" class="no-js "lang="en-US"> Amniotics - Medtech Alert
Friday, March 29, 2024
Amniotics | Pharmtech Focus

Amniotics

About Amniotics

Amniotics

Amniotics was born out of the discovery of novel stem cells in full term amniotic fluid. Research on these cells has demonstrated a number of unique properties in them, highlighting their extraordinary suitability for medical applications. These properties, in combination with safe collection, ethical agreeability, tissues and high cell counts harbour the promise of the exciting journey we have started pushing medical boundaries.

The science and research behind the discoveries on which the company is based has been carried out within the realms of the reputable Lund University in southern Sweden, one of its prime research centers BMC (Bio Medical Center) Research Center, and the university hospital in Lund. Therefore, Amniotics considers itself today to be uniquely positioned to translate stem cell technologies into novel and improved human therapeutics.

Our ultimate vision is to contribute to the successful treatment of serious human diseases by providing the very best cells for various regenerative medical applications. The fact that our cells are of neonatal source (and safely retrieved from the amniotic fluid from C-sections), means that they have greater genome integrity. And also other positive attributes of the neonatal source of our cells makes them superior to traditional sources of stem cells that are currently in therapeutic use.

As part of our commitment to providing the best cell therapeutics we are developing these for treatments with high unmet needs in collaboration with international renowned KOLs and partners. In a nutshell, we have designed and built a complete ecosystem for managing these cells in a safe, secure and controlled manner, which we are now expanding and scaling up. Our journey continues. We will push the boundaries of science within regenerative medicine to save and improve the lives of many.

#regenerativemedicine, #stemcells #therapies

Related Story

Amniotics AB Announces Positive Pre-clinical Proof-of-concept Results for PulmoStem™ in End-stage Lung Disease

April 29 2022

Amniotics AB (publ) (Nasdaq Stockholm: AMNI) today announced that PulmoStem™ significantly reduces the incidence of […]

Amniotics Receives Approval for Phase I/II Study of Pulmostem™ in Hospitalized COVID-19 Patients

April 6 2022

Amniotics AB (publ) (Nasdaq Stockholm: AMNI) today announced that it has received approval by regulatory […]

Amniotics Strengthens its Clinical and Regulatory Capabilities

January 25 2022

Amniotics AB (publ) (Nasdaq Stockholm: AMNI), a developer of novel cell therapy products, has appointed […]

Amniotics Secures Funding of SEK 4,8 Million from Vinnova to Develop Stem Cell Therapies

January 20 2022

Amniotics AB (publ) (Nasdaq Stockholm: AMNI) today announced that it has received a non-diluting grant […]

Amniotics Joins Vinnova Funded ’CAMP’ to Improve Outcome of Lung Transplantations with PulmoStem™

December 21 2021

Amniotics AB (publ) (Nasdaq Stockholm: AMNI), a developer of novel cell therapy products, today announced that […]

Stem Cell Therapy Company Amniotics Raises SEK 60 Million

July 13 2021

Amniotics AB (publ) (“Amniotics” or the “Company”), a stem cell therapy company has raised SEK60 million through […]